$6.35
-2.67 (-29.60%)
Open$7.96
Previous Close$9.02
Day High$7.96
Day Low$6.25
52W High$17.44
52W Low$6.01
Volume—
Avg Volume174.7K
Market Cap84.44M
P/E Ratio—
EPS$-13.02
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+129.0% upside
Current
$6.35
$6.35
Target
$14.54
$14.54
$12.76
$14.54 avg
$24.66
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.25M | 5.50M | 4.94M |
| Net Income | 1.19M | 1.50M | 1.15M |
| Profit Margin | 22.6% | 27.2% | 23.3% |
| EBITDA | 2.24M | 2.36M | 2.10M |
| Free Cash Flow | 844.4K | 896.3K | 789.1K |
| Rev Growth | +6.7% | -8.7% | -5.9% |
| Debt/Equity | 0.59 | 0.52 | 0.49 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |